Evidence map›Paper›PMID 41496712›Full record

ArticleJournal of the European Academy of Dermatology and Venereology : JEADV2026

Dupilumab in moderate-to-severe prurigo nodularis: Real-world data from early access program.

Marie Jachiet, Clémentine Toussaint, Valérie Dorizy-Vuong, Sophie Osdoit, Pierre-André Becherel, Emmanuelle Amazan, Julia Vanlerberghe, Mahtab Samimi, Claudia Soares Barbosa, Carine Vera and 5 more

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the European Academy of Dermatology and Venereology : JEADV, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Marie JachietDermatology, Saint-Louis Hospital, APHP and Paris Cité University, Paris, France.ORCID https://orcid.org/0000-0001-5286-9689
Clémentine ToussaintDermatology, Bordeaux Hospital, Bordeaux, France.
Valérie Dorizy-VuongDermatology, Bordeaux Hospital, Bordeaux, France.
Sophie OsdoitDermatology, Saint-Nazaire Hospital, Saint-Nazaire, France.
Pierre-André BecherelDermatology, Antony Hospital, Antony, France.
Emmanuelle AmazanDermatology, Martinique Hospital, Fort-de-France, France.
Julia VanlerbergheDermatology, Lille Hospital, Lille, France.
Mahtab SamimiDermatology, Tours Hospital, Tours, France.
Claudia Soares BarbosaPharmacovigilance, Sanofi, Gentilly, France.
Carine VeraOn Behalf of Sanofi - Global Medical Affairs - Biostatistics and Programming, IVIDATA Life Sciences, Paris, France.
Simmi WigginsDermatology, Sanofi, Reading, UK.
Véronique Marcadé FulcrandMedical Affairs, Sanofi, Gentilly, France.
Cédric MeyerMedical Affairs, Sanofi, Gentilly, France.
Laurent MiseryDermatology, Brest Hospital, Brest, France.ORCID https://orcid.org/0000-0001-8088-7059
Jean-David BouazizDermatology, Saint-Louis Hospital, APHP and Paris Cité University, Paris, France.ORCID https://orcid.org/0000-0002-4993-2461

Funding

This program was sponsored by Sanofi Winthrop Industrie and Regeneron Pharmaceuticals Inc.
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

chronic prurigodupilumabitchprurigo nodularisquality of lifereal‐world

Identifiers

PMID41496712
PMCPMC13308665

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.